Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...
What short‑term technical implications might this news have on the stock’s price action and trading volume?
Are there any upcoming regulatory milestones, product launches, or contracts that could offset the current revenue decline?
Will the revised guidance materially affect the company's valuation multiples (e.g., P/E, EV/Revenue)?
20 days ago